MDCG gui­d­ance on the tran­si­tio­nal pro­vi­si­ons in Arti­cle 120 MDR

Tran­si­tio­nal rules of Arti­cle 120 MDR

Arti­cle 120, Para­graphs (2) and (3) of the Medi­cal Devices Regu­la­ti­on (EU) 2017/745 (MDR) (PDF) sta­te that devices for which valid cer­ti­fi­ca­tes are avail­ab­le that were still issued by a Noti­fied Body under the Acti­ve Implan­ta­ble Medi­cal Devices Direc­ti­ve 90/385/EEC (AIMDD) or the Medi­cal Devices Direc­ti­ve 93/42/EEC (MDD) can still be pla­ced on the mar­ket or put into ser­vice after the MDR beco­mes app­li­ca­ble. Pre­re­qui­si­te for this is that the Noti­fied Body that issued the rele­vant cer­ti­fi­ca­te in accordance with the MDD or the AIMDD con­ti­nues to car­ry out, or is able to car­ry out, appro­pria­te sur­veil­lan­ce of all requi­re­ments for the devices it has cer­ti­fied. Gui­d­ance Docu­ment 2022–4 (PDF) sum­ma­ri­ses what is expec­ted of both manu­fac­tu­rers and Noti­fied Bodies with respect to “appro­pria­te sur­veil­lan­ce” under Arti­cle 120 MDR.

QMS requi­re­ments: MDD vs. MDR

In par­ti­cu­lar, to cla­ri­fy the ele­ments to be review­ed by Noti­fied Bodies, the gui­d­ance docu­ment exp­lains cer­tain obli­ga­ti­ons of manu­fac­tu­rers with respect to their qua­li­ty manage­ment systems.

Arti­cle 120(3) MDR requi­res that devices still pla­ced on the mar­ket or put into ser­vice under MDD/AIMDD cer­ti­fi­ca­ti­on con­ti­nue to com­ply with eit­her of the­se Direc­ti­ves and do not under­go signi­fi­cant chan­ges in design or inten­ded use. The­re­fo­re, in princip­le, the qua­li­ty manage­ment sys­tem appro­ved in accordance with the gui­de­li­nes must be main­tai­ned. Howe­ver, accord­ing to the first sub­pa­ra­graph of Arti­cle 120(3) MDR, all app­li­ca­ble requi­re­ments of Chap­ter VII of the MDR on post-market sur­veil­lan­ce, mar­ket sur­veil­lan­ce, vigi­lan­ce and regis­tra­ti­on of eco­no­mic ope­ra­tors for exis­ting pro­ducts must be obser­ved ins­tead of the cor­re­spon­ding requi­re­ments in the Directives.

MDR requi­re­ments other than post-market sur­veil­lan­ce, mar­ket sur­veil­lan­ce, vigi­lan­ce, regis­tra­ti­on of eco­no­mic ope­ra­tors and pro­ducts should in princip­le not app­ly to eco­no­mic ope­ra­tors in rela­ti­on to exis­ting products. 

This is whe­re the gui­d­ance docu­ment pro­ves par­ti­cu­lar­ly hel­pful to manu­fac­tu­rers by pro­vi­ding a com­pa­ra­ti­ve table of the qua­li­ty manage­ment sys­tem requi­re­ments in the MDD and MDR, which manu­fac­tu­rers can use to cla­ri­fy which MDD or AIMDD requi­re­ments are cove­r­ed by the MDR and which are not.

Gui­d­ance for Noti­fied Bodies and super­vi­so­ry authorities

Fur­ther­mo­re, the docu­ment pro­vi­des infor­ma­ti­on on the scope of duties of Noti­fied Bodies and super­vi­so­ry aut­ho­ri­ties with regard to pro­duct sur­veil­lan­ce of exis­ting pro­ducts during the tran­si­tio­nal pro­vi­si­ons, which can also be used by manu­fac­tu­rers to see what expec­ta­ti­ons they must reck­on with regar­ding their exis­ting pro­ducts in the con­text of audits and inspections.

Recom­men­da­ti­on for action

The Coör­di­na­ti­on Group’s gui­d­ance docu­ments do not reflect the offi­cial posi­ti­on of the Euro­pean Com­mis­si­on. Hence, the recom­men­da­ti­ons are not legal­ly bin­ding. Nevertheless, they are to be unders­tood as a valu­able inter­pre­ta­ti­on aid for eco­no­mic ope­ra­tors to com­pre­hend the still new MDR and IVDR. Manu­fac­tu­rers should keep an eye on MDCG publi­ca­ti­ons and check them in terms of rele­van­ce to their own pro­ducts. Fol­lowing the gui­d­ance docu­ments and set­ting up pro­ducts in accordance with them can signi­fi­cant­ly help to avoid “trou­ble” with Noti­fied Bodies and regu­la­to­ry aut­ho­ri­ties when com­pli­an­ce with the app­li­ca­ble regu­la­ti­ons is questioned.


Stay up-to-date

We use your e-mail address exclusively for sending our newsletter. You have the right to revoke your consent at any time with effect for the future. For further information, please refer to our privacy policy.